Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy

Journal of Gastroenterology

Volumn 42, Issue 7, 2007, Pages 533-538

  Hosokawa, Ayumu ^a,b   Sugiyama, Toshiro ^a   Ohtsu, Atsushi ^b   Doi, Toshihiko ^b   Hattori, Santa ^b   Kojima, Takashi ^b   Yano, Tomonori ^b   Minashi, Keiko ^b   Muto, Manabu ^b   Yoshida, Shigeaki ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Clinical practice; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER SURVIVAL; CANCER SURVIVOR; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; HYPERBILIRUBINEMIA; JAPAN; LEUKOPENIA; LIVER METASTASIS; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OXONIC ACID; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 34547593067     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-007-2059-3     Document Type: Article

References (19)

1. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37-41 8508427 10.1002/ 1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P 1:STN:280:ByyB1cvlvFM%3D
2. B Glimelius K Hoffman U Haglund O Nyren PO Sjoden 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189-90 8186165 1:STN:280:ByuB2c3mvVY%3D
3. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-91 7533517 1:STN:280:ByqC1cnjvVA%3D
4. JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper 1999 Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer. Results of a randomized trial Br J Cancer 80 269-72 10390007 10.1038/sj.bjc.6690350 1:CAS:528:DyaK1MXjtFyksbo%3D
5. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648-57 10894863 1:CAS:528:DC%2BD3cXls12iurk%3D
6. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205) J Clin Oncol 21 54-9 12506170 10.1200/JCO.2003.04.130 1:CAS:528:DC%2BD2cXpsVWru7k%3D
7. NK Kim YS Park DS Heo C Suh SY Kim KC Park 1993 A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813-8 8508349 10.1002/ 1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5 1:STN:280:ByyB1cvkvFQ%3D
8. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group J Clin Oncol 24 4991-7 17075117 10.1200/JCO.2006.06.8429 1:CAS:528:DC%2BD28Xht1GnurzJ
9. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-20 9893658 10.1016/S0959-8049(98)00211-1 1:CAS:528:DyaK1cXntlShurw%3D
10. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fuorouracil, in advanced gastric cancer Oncology 58 191-7 10765119 10.1159/000012099 1:CAS:528:DC%2BD3cXjvVeitr4%3D
11. F Nagashima A Ohtsu S Yoshida K Ito 2005 Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6-11 15747168 10.1007/s10120-004-0306-3
12. O Kobayashi K Konishi M Kanari H Cho T Yoshikawa A Tsuburaya 2002 Unusual survival for more than 2 years with peritoneal metastases of gastric cancer Gastric Cancer 5 47-50 12021860 10.1007/s101200200007
13. K Fujitani T Tsujinaka M Hirao 2003 Feasibility study of S-1 for respectable gastric cancer with peritoneal seeding Hepatogastroenterology 50 889-92 12828112
14. H Osugi N Takada M Takemura S Kaseno S Lee M Ueno 2002 Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination Oncol Rep 9 811-5 12066214 1:CAS:528:DC%2BD38XltlGrsrk%3D
15. T Mori Y Fujiwara M Yano S Tamura T Yasuda S Takiguchi 2003 Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer Gastric Cancer 6 13-8 12775014 10.1007/ s10120-003-0226-7
16. M Yoshida A Ohtsu N Boku Y Miyata K Shirao Y Shimada 2004 Long-term survival and prognostic factors with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study Jpn J Clin Oncol 34 654-9 15613554 10.1093/jjco/hyh120
17. P Rougier M Ducreux M Mahjoubi JP Pignon S Bellefqih J Oliveira 1994 Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis Eur J Cancer 30A 1263-9 7999410 10.1016/0959-8049(94)90170-8 1:STN:280:ByqD1M3jslc%3D
18. C Louvet F Carrat F Mal M Mabro K Beerblock JC Vaillant 2003 Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen) Cancer Invest 21 14-20 12643005 10.1081/CNV-120016399 1:CAS:528:DC%2BD3sXisF2mtrg%3D
19. I Chau AR Norman D Cunningham JS Waters J Oates PJ Ross 2004 Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395-403 15197201 10.1200/JCO.2004.08.154